Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Corcept Therapeutics (CORT)

Corcept Therapeutics (CORT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,571,364
  • Shares Outstanding, K 114,281
  • Annual Sales, $ 251,250 K
  • Annual Income, $ 75,410 K
  • 60-Month Beta 1.32
  • Price/Sales 6.05
  • Price/Cash Flow 20.30
  • Price/Book 4.52

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 0.24
  • Number of Estimates 4
  • High Estimate 0.26
  • Low Estimate 0.20
  • Prior Year 0.18
  • Growth Rate Est. (year over year) +33.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.17 +23.55%
on 11/20/19
17.48 -21.05%
on 11/19/19
-1.21 (-8.06%)
since 11/08/19
3-Month
11.17 +23.55%
on 11/20/19
17.48 -21.05%
on 11/19/19
+0.77 (+5.91%)
since 09/10/19
52-Week
9.14 +50.98%
on 02/05/19
19.48 -29.16%
on 12/12/18
+0.82 (+6.32%)
since 12/10/18

Most Recent Stories

More News
Why Is Corcept (CORT) Down 8.9% Since Last Earnings Report?

Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

CORT : 13.80 (+0.36%)
Can The Uptrend Continue for Corcept Therapeutics?

As of late, it has definitely been a great time to be an investor Corcept Therapeutics.

CORT : 13.80 (+0.36%)
Options Traders Expect Huge Moves in Corcept (CORT) Stock

Investors need to pay close attention to Corcept (CORT) stock based on the movements in the options market lately.

CORT : 13.80 (+0.36%)
Corcept (CORT) Earnings Beat in Q3, Korlym Boosts Sales

Corcept (CORT) rides high on both earnings and revenue beat in the third quarter.

LLY : 120.65 (+0.34%)
CELG : 108.24 (+0.10%)
CORT : 13.80 (+0.36%)
TRIL : 0.32 (unch)
Corcept Therapeutics (CORT) Surpasses Q3 Earnings and Revenue Estimates

Corcept (CORT) delivered earnings and revenue surprises of 15.79% and 5.05%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

CORT : 13.80 (+0.36%)
Corcept: 3Q Earnings Snapshot

MENLO PARK, Calif. (AP) _ Corcept Therapeutics Inc. (CORT) on Thursday reported third-quarter net income of $26.3 million.

CORT : 13.80 (+0.36%)
Corcept Therapeutics Announces Third quarter 2019 Financial Results and provides corporate update

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating...

CORT : 13.80 (+0.36%)
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call

Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update on November 7, 2019. The company will also host a conference...

CORT : 13.80 (+0.36%)
Why Corcept (CORT) is Poised to Beat Earnings Estimates Again

Corcept (CORT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

CORT : 13.80 (+0.36%)
Shareholder Alert: Robbins Arroyo Announces Another Complaint Filed Against Corcept Therapeutics Incorporated (CORT)

Shareholder rights law firm Robbins Arroyo LLP announces that a purchaser of Corcept Therapeutics Incorporated (NASDAQ: CORT) filed a complaint against the company's officers and directors for breaches...

CORT : 13.80 (+0.36%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade CORT with:

Business Summary

Corcept Therapeutics Incorporated is a pharmaceutical company. It is engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The company focuses on disorders that are associated with a steroid hormone called cortisol....

See More

Key Turning Points

2nd Resistance Point 14.13
1st Resistance Point 13.97
Last Price 13.80
1st Support Level 13.65
2nd Support Level 13.50

See More

52-Week High 19.48
Fibonacci 61.8% 15.53
Fibonacci 50% 14.31
Last Price 13.80
Fibonacci 38.2% 13.09
52-Week Low 9.14

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar